The prospective preventative HIV vaccine based on modified poliovirus

Medical Hypotheses

Volumn 68, Issue 6, 2007, Pages 1258-1261

  Zhang, Yang de ^a   Lu, Xiao lin ^a   Li, Nian feng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ORAL POLIOMYELITIS VACCINE; VIRUS VECTOR;

ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CHIMERA; DRUG EFFICACY; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; MUCOSAL IMMUNITY; NONHUMAN; PANDEMIC; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS VIRULENCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; GENES, VIRAL; GENETIC VECTORS; HIV ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; MODELS, IMMUNOLOGICAL; POLIOVIRUS; VIRULENCE;

ANIMALIA; POLIOVIRUS;

EID: 33947646476     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.07.062     Document Type: Article

References (32)

1. Gayle H.D. Expanding access to HIV prevention. Aids Res Ther 3 (2006) 2
2. Natuk R.J., Chanda P.K., Lubeck M.D., et al. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model. Proc Natl Acad Sci USA 89 (1992) 7777-7781
3. Smith S.M. HIV vaccine development in the nonhuman primate model of AIDS. J Biomed Sci 9 (2002) 100-111
4. Dennehy P.H. Active immunization in the united states: developments over the past decade. Clin Microbiol Rev 14 (2001) 872-908
5. Chen X., Rock M.T., Hammonds J., et al. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses. J Virol 79 (2005) 5537-5547
6. Smith K.A. The HIV vaccine saga. Med Immunol 2 (2003) 1
7. Oh S., Berzofsky J.A., Burke D.S., Waldmann T.A., and Perera L.P. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci USA 100 (2003) 3392-3397
8. Fang Z.-Y., Limbach K., Tartaglia J., Hammonds J., Chen X., and Spearman P. Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells. Virology 291 (2001) 272-284
9. Lubeck M.D., Natuk R., Myagkikh M., et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 3 (1997) 651-658
10. Fouts T.R., DeVico A.L., Onyabe D.Y., et al. Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1. Fems Immunol Med Microbiol 37 (2003) 129-134
11. Moldoveanu Z., Porter D.C., Lu A., Mcpherson S., and Morrow C.D. Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins. Vaccine 13 (1995) 1013-1022
12. Elswood B.F., and Stricker R.B. Polio vaccines and the origin of AIDS. Med Hypotheses 42 (1994) 347-354
13. Nicastri E., Ercoli L., Sarmati L., et al. Human immunodeficiency virus-1 specific and natural cellular immunity in HIV seronegative subjects with multiple sexual exposures to virus. J Med Virol 64 (2001) 232-237
14. Andino R., Silvera D., Suggett S.D., et al. Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science 265 (1994) 1448-1451
15. Crotty S., Miller C.J., Lohman B.L., et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J Virol 75 (2001) 7435-7452
16. Mandl S., Sigal L.J., Rock K.L., and Andino R. Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen. Proc Natl Acad Sci USA 95 (1998) 8216-8221
17. Kiyono H., Miller C.J., Yichen L., et al. The common mucosal immune system for the reproductive tract: basic principles applied toward an AIDS vaccine. Adv Drug Deliv Rev 18 (1995) 23-51
18. Percy N., Barclay W.S., Sullivan M., and Almond J.W. A poliovirus replicon containing the chloramphenicol acetyltransferase gene can be used to study the replication and encapsidation of poliovirus RNA. J Virol 66 (1992) 5040-5046
19. Mattion N.M., Reilly P.A., DiMichele S.J., Crowley J.C., and Weeks-Levy C. Attenuated poliovirus strain as a live vector: expression of regions of rotavirus outer capsid protein VP7 by using recombinant Sabin 3 viruses. J Virol 68 (1994) 3925-3933
20. Choi W.S., Pal-Ghosh R., and Morrow C.D. Expression of human immunodeficiency virus type 1 (HIV-1) gag, pol, and env proteins from chimeric HIV-1-poliovirus minireplicons. J Virol 65 (1991) 2875-2883
21. Porter D.C., Melsen L.R., Compans R.W., and Morrow C.D. Release of virus-like particles from cells infected with poliovirus replicons which express HIV-1 gag. J Virol 70 (1996) 2643-2649
22. Palese P. RNA virus vectors: where are we and where do we need to go?. Proc Natl Acad Sci USA 95 (1998) 12750-12752
23. Murray K.E., Steil B.P., Roberts A.W., and Barton D.J. Replication of poliovirus RNA with complete internal ribosome entry site deletions. J Virol 78 (2004) 1393-1402
24. Nomoto A., Koike S., and Aoki J. Tissue tropism and species specificity of poliovirus infection. Trends Microbil 2 (1994) 47-51
25. Ida-Hosonuma M., Iwasaki T., Yoshikawa T., et al. The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol 79 (2005) 4460-4469
26. Marti{dotless}́n J., Samoilovich E., Dunn G., et al. Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis. J Virol 76 (2002) 10921-10928
27. Yanagiya A., Jia Q., Ohka S., Horie H., and Nomoto A. Blockade of the poliovirus-induced cytopathic effect in neural cells by monoclonal antibody against poliovirus or the human poliovirus receptor. J Virol 79 (2005) 1523-1532
28. Dudek T., and Knipe D.M. Replication-defective viruses as vaccines and vaccine vectors. Virology 344 (2006) 230-239
29. Mandl S., Sigal L.J., Rock K.L., and Andino R. Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen. Proc Natl Acad Sci 95 (1998) 8216-8221
30. Crotty S., Miller C.J., Lohman B.L., et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J Virol 75 (2001) 7435-7452
31. Jenkins O., Cason J., Burke K.L., et al. An antigen chimera of poliovirus induces antibodies against human papillomavirus type 16. J Virol 64 (1990) 1201-1206
32. Berzofsky J.A., Ahlers J.D., Janik J., Morris J., Oh S., Terabe M., et al. Progress on new vaccine strategies against chronic viral infections. J Clin Invest 114 (2004) 450-462